|
Contents
|
Staging of testicular cancer
Τ (Primary tumor)
| pTis | Intratubular in situ carcinoma (in situ) |
|---|---|
| pT1 | Tumor confined in the testicular parenchyma and epididymis without vascular / lymphatic infiltration: The tumor can invade the tunica albuginea but not the tunica vaginalis |
| pT2 | Tumor in the testicle and the epididymis with vascular-lymphatic invasion or tumor infiltrating the tunica vaginalis |
| pT3 | Invasion of the spermatic cord with or without vascular / lymphatic infiltration |
| pT4 | Invasion of the scrotum with or without vascular / lymphatic infiltration |
Ν (Retroperitoneal lymph-nodes, clinical assessment)
| Ν0 | Without lymph node metastasis |
|---|---|
| Ν1 | Lymph-node mass <2 cm or multiple infiltrated lymph nodes, none> 2 cm |
| Ν2 | Lymph-node mass <2-5 cm or multiple infiltrated lymph nodes, none> 5 cm |
| Ν3 | Lymph-node mass > 5 cm |
Μ (Distal metastases, clinical assessment)
| Μ0 | Absence of distal metastases |
|---|---|
| Μ1 | Presence of distal metastases |
| Μ1a | Invasion of lymph-nodes (except from the retroperitoneal lymph-nodes) or pulmonary metastases |
| M1b | Distant metastases in liver, brain, bones |
Tumor markers (S)
| S0 | Normal tumor markers |
|---|---|
| S1 | LDH < 1,5 times the normal value, β-hCG < 5.000 UI/ml, AFP < 1000 ng/ml |
| S2 | LDH 1,5-10 times the normal value, β-hCG 5.000-50.000 UI/ml, AFP 1000- 10.000 ng/ml |
| S3 | LDH > 10 times the normal value, β-hCG > 50.000 UI/ml, AFP > 10.000 ng/ml |
|
Name |
|
|---|---|
|
Special features |
For advanced testicular tumors from germ cells |
|
What does it calculate? |
Probability of complete response to chemotherapy (platinum) in patients with testicular cancer |
|
Creator |
Bajorin DF, Memorial Sloan-Kettering Cancer Center |
|
First publication |
Bajorin DF, et al. J Clin Oncol. 1998; 16: 707-15 |
|
References |
19 |
|
Institution / name |
Fox Chase Cancer Center, Philadelphia, Pennsylvania USA |
|
Link |
http://labs.fccc.edu/nomograms/nomogram.php?id=41&audience=1 |
|
ISUD Evaluation |
* |
|
Name |
|
|---|---|
|
Special features |
For non seminomatous tumors submitted to chemotherapy (cisplatin) |
|
What does it calculate? |
Assessment of the 2-year survival of patients with testicular cancer |
|
Creator |
Fosså SD, The Norwegian Radium Hospital, Montebello, Oslo |
|
First publication |
Fosså SD, et al. Br J Cancer. 1999; 80: 1392-9 |
|
References |
75 |
|
Institution / name |
Fox Chase Cancer Center, Philadelphia, Pennsylvania USA |
|
Link |
http://labs.fccc.edu/nomograms/nomogram.php?id=42&audience=1 |
|
ISUD Evaluation |
** |
|
Name |
|
|---|---|
|
Special features |
For non seminomatous tumors submitted to chemotherapy (cisplatin) |
|
What does it calculate? |
Staging |
|
Creator |
National Comprehensive Cancer Network |
|
First publication |
NCCN Guidelines, Version 1.2011 |
|
References |
|
|
Institution / name |
Fox Chase Cancer Center, Philadelphia, Pennsylvania USA |
|
Link |
|
|
ISUD Evaluation |
*** |